CEACAM5 and colorectal carcinoma: More importantly, when compared with IGFBP-1 alone, ROC analysis showed that the combination of IGFBP-1 and CEA, IGFBP-1 and CA19-9 or the three-biomarker panel (IGFBP-1+CEA+CA19-9) had a minute improvement of AUC to distinguish all stage CRC patients from controls (Supplementary Fig. S2A, Table 3).